A French court ruled that families of children who suffered side effects from the epilepsy medicine Depakine can join in a class-action lawsuit against drugmaker Sanofi.
The company should have warned of the risk of birth defects for pregnant women taking the medicine as early as 1984, a Paris court said Wednesday. Instead it only took those steps in 2003, it said, calling the product that was sold for decades “defective.”
Depakine is a powerful anti-epileptic drug that’s on the World Health Organization’s list of essential medicines, but it has been blamed for neuro-development problems in tens of thousands of children in a long-running court case in Sanofi’s home market. A class-action lawsuit would be a legal first in France, according to Agence France-Presse.
Sanofi said it will appeal the decision. The drugmaker said it has co-operated with authorities and hasn’t been found responsible in any legal proceedings involving Depakine. The stock rose less than 1% in Paris trading.
The class action lawsuit may also be directed at Sanofi’s insurer, a unit of Allianz AG, the court said.
Photograph: Logo on the Sanofi exhibition stand at the Viva Technology conference at Porte de Versailles exhibition center in Paris, France, on Friday, June 18, 2021. Photo credit: Nathan Laine/Bloomberg.
Was this article valuable?
Here are more articles you may enjoy.
Product Liability Verdicts Are on the Rise but There Are Ways to Avoid Them 
Surveys Show Concerns About Florida Market, But Consumers Are Warming Up 
How ‘Super Roofs’ Reward Insurers, Cat Bond Investors and Homeowners 
Death of Teenager on Carnival Cruise Ship Ruled a Homicide 
